Replimune Group (NASDAQ:REPL) Price Target Raised to $9.00 at Wedbush

Replimune Group (NASDAQ:REPL) had its price target hoisted by Wedbush from $6.00 to $9.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Wedbush’s target price would suggest a potential downside of 19.64% from the stock’s current price.

Several other brokerages also recently commented on REPL. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. JPMorgan Chase & Co. upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 target price on the stock in a research note on Friday. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a report on Friday, April 10th. Finally, HC Wainwright reissued a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $6.38.

Replimune Group Trading Down 3.7%

NASDAQ REPL opened at $11.20 on Tuesday. Replimune Group has a 12 month low of $1.50 and a 12 month high of $13.24. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. The stock’s fifty day moving average price is $6.41 and its 200-day moving average price is $7.29. The stock has a market cap of $924.78 million, a P/E ratio of -3.26 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities analysts forecast that Replimune Group will post -3.39 EPS for the current fiscal year.

Insider Activity at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the sale, the insider directly owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Replimune Group by 17.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after acquiring an additional 6,653 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Replimune Group by 2.8% during the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after purchasing an additional 33,574 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after purchasing an additional 119,145 shares during the last quarter. Rhumbline Advisers lifted its position in Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after purchasing an additional 6,616 shares during the period. Finally, Sei Investments Co. lifted its position in Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after purchasing an additional 18,263 shares during the period. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.